ArticleCommunications biology2021
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus.
Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 44 citations in OpenAlex.
- Assessing Seroprevalence and Infection Dynamics of Oncogenic Gammaherpesviruses in South African Paediatric Patients Presenting with Inflammatory Conditions.International journal of molecular sciences · 2026Article
- Article
- A KSHV-targeted small molecule efficiently blocks SARS-CoV-2 infection via inhibiting expression of EGFR and Cyclin A2.Emerging microbes & infections · 2025Article
- 1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea.Biomarker research · 2025Article
- Review
- Atypical cellular neurothekeoma: a case report with a novel NF1 mutation.Diagnostic pathology · 2024Article
- Kaposi Sarcoma as a Possible Cutaneous Adverse Effect of ChAdOx1 nCov-19 Vaccine: A Case Report.Vaccines · 2024Article
- Unilateral conjunctival Classic Kaposi Sarcoma following a COVID 19 booster.American journal of ophthalmology case reports · 2024Article
- Article
- Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.NPJ science of food · 2024Review
- Sporadic Kaposi Sarcoma Following a COVID-19 Vaccine: Mere Coincidence or Something More?Cureus · 2024Article
- The Impact of Co-Infections for Human Gammaherpesvirus Infection and Associated Pathologies.International journal of molecular sciences · 2023Review
- Towards Understanding Long COVID: SARS-CoV-2 Strikes the Host Cell Nucleus.Pathogens (Basel, Switzerland) · 2023Review
- SARS-CoV-2 infection as a potential risk factor for the development of cancer.Frontiers in molecular biosciences · 2023Review
- SARS-CoV-2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?Journal of medical virology · 2022Review
- SARS-CoV-2 and cancer: the intriguing and informative cross-talk.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Article
- Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.Pharmaceutics · 2022Review
- Kaposi Sarcoma, a Trifecta of Pathogenic Mechanisms.Diagnostics (Basel, Switzerland) · 2022Review
- Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report.Clinical and experimental vaccine research · 2022Article
- SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers.International journal of hematology-oncology and stem cell research · 2022Review
Corrections and comments
- Update of
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected almost one hundred million people since the end of 2019, killed over two million, and caused worldwide social and economic disruption. Because the mechanisms of SARS-CoV-2 infection of host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy. Besides severe respiratory and systematic symptoms, several comorbidities increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we report that SARS-CoV-2 encoded proteins and some currently used anti-COVID-19 drugs are able to induce lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses, through manipulation of intracellular signaling pathways. Our data indicate that those KSHV + patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.